Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.
Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer
Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers
FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC
March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma